October 19, 2020 -- Ultimovacs reported five-year overall survival data from its phase I clinical trial evaluating UV1, a universal cancer vaccine candidate, in patients with non-small cell lung cancer.
UV1 is a peptide-based vaccine which induces specific T-cell responses against the universal cancer antigen, telomerase. The product has been developed as a cancer vaccine and can be used in combination with other immunotherapies that require ongoing T-cell responses for their mode of action.
The phase I clinical trial included a total of 18 non-small cell lung cancer patients whose disease has not processed after receiving at least a second line treatment with chemotherapy. These patients received UV1 monotherapy as a maintenance treatment. In the trial, each patient reached at least 60 months of follow-up treatment with UV1. After five years, the overall survival rate was 33% and the median progression free survival rate was 10.7 months.
UV1 is also being evaluated in three phase II combination clinical trials. Ultimovacs anticipates announcing data from these studies in 2022.